MedMira Initiates Clinical Trial for Multiplo® TP/HIV Self-Test in Canada

MedMira Inc., based in Halifax, Nova Scotia, has embarked on a pivotal clinical trial to evaluate its Multiplo® TP/HIV rapid test as a self-test in Canada. The trial, launched earlier than expected, received approval from Health Canada to bypass additional testing requirements. Initial testing has begun at two Canadian health centers, marking significant progress in delivering self-testing options for HIV and syphilis.

Collaborating with REACH Nexus, the trial is funded by the Canadian Institutes of Health Research. The aim is to secure a label claim for self-testing, which is seen as a critical step in combating the rising number of HIV and syphilis cases in the country. Recent data reveals a concerning increase in infections, with new HIV diagnoses increasing significantly from 2022 to 2023.

By facilitating self-testing, MedMira aims to offer a quick, accurate, and private solution for individuals to determine their status and access necessary care. Clinical trials are expanding across multiple provinces, reflecting a priority on public health and empowerment through self-testing.